Send to

Choose Destination
Sci Rep. 2016 Oct 18;6:35695. doi: 10.1038/srep35695.

Influence of age on androgen deprivation therapy-associated Alzheimer's disease.

Author information

Stanford Center for Biomedical Informatics Research, Stanford University, 1265 Welch Road, Stanford, California, 94305, USA.
Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Boulevard, Philadelphia, Pennsylvania, 19104, USA.
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, 10029, USA.
Stanford Cardiovascular Institute, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California, 94305, USA.


We recently found an association between androgen deprivation therapy (ADT) and Alzheimer's disease. As Alzheimer's disease is a disease of advanced age, we hypothesize that older individuals on ADT may be at greatest risk. We conducted a retrospective multi-institutional analysis among 16,888 individuals with prostate cancer using an informatics approach. We tested the effect of ADT on Alzheimer's disease using Kaplan-Meier age stratified analyses in a propensity score matched cohort. We found a lower cumulative probability of remaining Alzheimer's disease-free between non-ADT users age ≥70 versus those age <70 years (p < 0.001) and between ADT versus non-ADT users ≥70 years (p = 0.034). The 5-year probability of developing Alzheimer's disease was 2.9%, 1.9% and 0.5% among ADT users ≥70, non-ADT users ≥70 and individuals <70 years, respectively. Compared to younger individuals older men on ADT may have the greatest absolute Alzheimer's disease risk. Future work should investigate the ADT Alzheimer's disease association in advanced age populations given the greater potential clinical impact.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center